Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
128298-82-8
|
| gptkbp:clinicalTrialPhase |
Phase II (as of 2023)
|
| gptkbp:developedBy |
gptkb:Parkinson's_disease
gptkb:Schering-Plough schizophrenia obesity Tourette syndrome |
| gptkbp:hasInChIKey |
QJQYQKZQJXKJQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C16H14ClNO2
|
| gptkbp:hasSMILES |
C1CC2=C(C(=CC=C2Cl)C3=CC=CC=C3C(=O)O)N1
|
| https://www.w3.org/2000/01/rdf-schema#label |
ecopipam
|
| gptkbp:IUPACName |
(6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzoic acid
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
dopamine D1 receptor antagonist
dopamine D1 receptor partial agonist |
| gptkbp:molecularWeight |
287.74 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL2103847
132747 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
SCH 39166
SCH-39166 |
| gptkbp:target |
gptkb:dopamine_D1_receptor
gptkb:dopamine_D5_receptor |
| gptkbp:UNII |
6QX1C2VV9S
|
| gptkbp:bfsParent |
gptkb:dopamine_receptor_D1
|
| gptkbp:bfsLayer |
7
|